203 related articles for article (PubMed ID: 31197259)
1. Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
Giménez N; Schulz R; Higashi M; Aymerich M; Villamor N; Delgado J; Juan M; López-Guerra M; Campo E; Rosich L; Seiffert M; Colomer D
Leukemia; 2020 Jan; 34(1):100-114. PubMed ID: 31197259
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
Delvecchio VS; Sana I; Mantione ME; Vilia MG; Ranghetti P; Rovida A; Angelillo P; Scarfò L; Ghia P; Muzio M
Br J Haematol; 2020 May; 189(3):475-488. PubMed ID: 32057093
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling.
De Nardo D; Balka KR; Cardona Gloria Y; Rao VR; Latz E; Masters SL
J Biol Chem; 2018 Sep; 293(39):15195-15207. PubMed ID: 30076215
[TBL] [Abstract][Full Text] [Related]
4. MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
Improgo MR; Tesar B; Klitgaard JL; Magori-Cohen R; Yu L; Kasar S; Chaudhary D; Miao W; Fernandes SM; Hoang K; Westlin WF; Kim HT; Brown JR
Br J Haematol; 2019 Mar; 184(6):925-936. PubMed ID: 30537114
[TBL] [Abstract][Full Text] [Related]
5. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.
De S; Karim F; Kiessu E; Cushing L; Lin LL; Ghandil P; Hoarau C; Casanova JL; Puel A; Rao VR
J Biol Chem; 2018 Sep; 293(39):15208-15220. PubMed ID: 30115681
[TBL] [Abstract][Full Text] [Related]
7. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
8. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
9. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.
Martínez-Trillos A; Pinyol M; Navarro A; Aymerich M; Jares P; Juan M; Rozman M; Colomer D; Delgado J; Giné E; González-Díaz M; Hernández-Rivas JM; Colado E; Rayón C; Payer AR; Terol MJ; Navarro B; Quesada V; Puente XS; Rozman C; López-Otín C; Campo E; López-Guillermo A; Villamor N
Blood; 2014 Jun; 123(24):3790-6. PubMed ID: 24782504
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
[TBL] [Abstract][Full Text] [Related]
12. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer.
Li Q; Chen Y; Zhang D; Grossman J; Li L; Khurana N; Jiang H; Grierson PM; Herndon J; DeNardo DG; Challen GA; Liu J; Ruzinova MB; Fields RC; Lim KH
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31527315
[TBL] [Abstract][Full Text] [Related]
13. Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
Martines C; Chakraborty S; Vujovikj M; Gobessi S; Vaisitti T; Deaglio S; Laurenti L; Dimovski AJ; Efremov DG
Blood; 2022 Dec; 140(22):2335-2347. PubMed ID: 36084319
[TBL] [Abstract][Full Text] [Related]
14. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
Loiarro M; Capolunghi F; Fantò N; Gallo G; Campo S; Arseni B; Carsetti R; Carminati P; De Santis R; Ruggiero V; Sette C
J Leukoc Biol; 2007 Oct; 82(4):801-10. PubMed ID: 17548806
[TBL] [Abstract][Full Text] [Related]
15. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling.
Lin SC; Lo YC; Wu H
Nature; 2010 Jun; 465(7300):885-90. PubMed ID: 20485341
[TBL] [Abstract][Full Text] [Related]
16. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
17. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
Li X
Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
[TBL] [Abstract][Full Text] [Related]
18. Cloning and functional characterization of IRAK4 in large yellow croaker (Larimichthys crocea) that associates with MyD88 but impairs NF-κB activation.
Zou PF; Huang XN; Yao CL; Sun QX; Li Y; Zhu Q; Yu ZX; Fan ZJ
Fish Shellfish Immunol; 2017 Apr; 63():452-464. PubMed ID: 27989863
[TBL] [Abstract][Full Text] [Related]
19. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor-9 (TLR-9) deficiency alleviates optic nerve injury (ONI) by inhibiting inflammatory response in vivo and in vitro.
Zhang L; Li X
Exp Cell Res; 2020 Nov; 396(1):112159. PubMed ID: 32652081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
